Navigation Links
Inflazyme Announces Outcome of Review of Phase 2b Asthma Study:,Potential Mitigating Factors Identified which Prevent Clear,Interpretation of Results

ent in their asthma independent of treatment with IPL512,602.

Finally, a large proportion of the patients were recruited during the summer allergy season, and the patients’ allergies might have diminished during the treatment phase of the trial as the allergy season waned. Resolution of allergic rhinitis could improve asthma symptoms and other measures of asthma control in all patients independent of treatment.

Our Phase 2b study was of a standard design generally used in this setting, such that these issues were not anticipated. However, taken together, we believe these issues nullify interpretation of the Phase 2b study.

Inflazyme believes that IPL512,602 would benefit from additional clinical investigation to confirm its potential as an oral treatment for asthma. The Company has significant clinical data from the earlier Phase 2a study in mild to moderate asthmatics completed by Aventis pharma (now sanofi-aventis) in June 2004, and substantial preclinical evidence indicating that the drug has efficacy in asthma. Today, Inflazyme has insufficient cash resources to conduct additional clinical trials with this product. Inflazyme plans to share these findings with other parties in an attempt to realize commercial value for this program.

About Inflazyme

Inflazyme Pharmaceuticals is a biopharmaceutical company pioneering medical breakthroughs to transform the lives of patients with respiratory and inflammatory diseases worldwide.Further information on the Company may be obtained from its website at www.inflazyme.com.

This news release contains certain “forward-looking statements” and “forward-looking information” which may include but is not limited to statements in respect of our future financial position or operations. Words like "believe", "intend", "may", "expect", “anticipate”, “plan”, “should” and oth
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:9/5/2008)... BOCA RATON, Fla., Sept. 5 /PRNewswire-USNewswire/...ip Board recently awarded Florida,Atlantic Univers...d,professor and director of the Center for Molecul...midt College of Science, and CHS,Resources LLC (CH...rch,Commercialization Assistance Grant program (SU...
(Date:9/5/2008)... VIENNA, Va., Sept. 5 /- CE...at it presented new rheumatoid arthritis data,at t...sterdam. The data,presented by Dr. Daniel Zimmerm...munology of CEL-SCI, indicate that CEL-SCI,s rheum...ds the permanent tissue damage,caused by rheumatoi...
(Date:9/5/2008)... MORGANTOWN, W.Va., Sept. 5 /PRNewswire-USNewswire...sity has shown that U.S. immigrants from,India and...try, increasing,their risks of prostate cancer amo...., "Breast cancer and prostate cancer develop due...festyle play a major role in these cancers,",said ...
(Date:9/4/2008)... MELBOURNE, Australia, Sept. 4 /- Cyt... commencing enrolment for its Phase Ib/II,study of...nticancer agent,in patients with an aggressive fo...e (GBM)., The GBM clinical trial is the first Pha...or indications for the company and the second in i...
Breaking Medicine Technology:Major State Grant Accelerates Research and Development of Novel Cancer Therapy 2Major State Grant Accelerates Research and Development of Novel Cancer Therapy 3Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 2Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 3Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 4Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks 2Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3Guardian Survey 3A Employees Are Confused About Their Health Coverage and Have No Plans for Healthcare in Retirement 19492 1Guardian Survey 3A Employees Are Confused About Their Health Coverage and Have No Plans for Healthcare in Retirement 19492 2Guardian Survey 3A Employees Are Confused About Their Health Coverage and Have No Plans for Healthcare in Retirement 19492 3Guardian Survey 3A Employees Are Confused About Their Health Coverage and Have No Plans for Healthcare in Retirement 19492 4Guardian Survey 3A Employees Are Confused About Their Health Coverage and Have No Plans for Healthcare in Retirement 19492 5BioElectronics Announces Conference Call to Update Investors on Growth Initiatives 5443 1BioElectronics Announces Conference Call to Update Investors on Growth Initiatives 5443 2BioElectronics Announces Conference Call to Update Investors on Growth Initiatives 5443 3Duane Reade Announces Proud Sponsorship of AIDS Walk New York 19488 1Duane Reade Announces Proud Sponsorship of AIDS Walk New York 19488 2Summit VetPharm Announces Grand Prize and March Winner in its Great Vectra 3D 28TM 29 24125 000 Giveaway 19483 1Summit VetPharm Announces Grand Prize and March Winner in its Great Vectra 3D 28TM 29 24125 000 Giveaway 19483 2
...ILLSIDE, NJ, March 12, 2007—InB:Biotechnolog...f Integrated BioPharma,Inc. (NASDAQ: INBP), today...accines against HPV, anthrax and plague made using...echnology. The,studies were conducted by the Fraun..., the Contract Research Organization led by Dr.,Vi...
...Tyrima Demonstrates Good Safety Profile and Excell...E PARK, N.C., March 13, 2007 /PRNewswire/ --,CeNeR...ping and,commercializing innovative treatments for...ounced top-line results from a Phase I,clinical tr...tment,of depression and anxiety. In this study, Ty...
Other Medicine Technology:Integrated BioPharma's Proprietary Vaccine Technology Achieves,Strong Positive Results 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3
(Date:9/5/2008)... need to know what triggers them, experts say , ...you are one of the 36 million Americans who suffer...United States that is free from pollen and other a...gies don,t only happen in the spring, they can be ...the most challenging cities to live in are Greensb...
(Date:9/5/2008)...wire-USNewswire/ -- Speaker Nancy Pelosi,issued th... of the "Stand,Up to Cancer" telethon, to be aired... in our country who has not seen a loved one,suffe...s annually, and each,year there are more than 1.4 ...r to make eradicating the scourge of cancer a nati...
(Date:9/5/2008)...RNewswire/ -- On Saturday, September 6, PARI,Respi...twork show Today,s,Family as part of their "Breath... medical device company that provides patients, su...d compressors that deliver needed,medications dire... lives of those affected by respiratory,diseases a...
(Date:9/5/2008)...wire-USNewswire/ -- As the general election,campai...n of Independent,Business ( http://www.nfib.com ) ...a greater focus on the healthcare concerns of smal... conventions are over, NFIB,is asking both candida...ced,by small businesses as they further develop th...
Breaking Medicine News(10 mins):Health News:No Place Safe From Allergies 2Health News:PARI Respiratory Equipment Featured on Oxygen Network 2Health News:Conventions Conclude, Fall Campaign Begins: NFIB Looks for More Focus on Small Business Healthcare Concerns 2Health News:Conventions Conclude, Fall Campaign Begins: NFIB Looks for More Focus on Small Business Healthcare Concerns 3
...che Diagnostics today announces that it has comple...merger agreement with BioVeris for approximately $...iagnostics now owns the patents for Electrochemilu...expand its immunochemistry business from the human...
...arly 100 people have been bitten and injured by a ...e no anti-rabies vaccines in the government hospit..., the jackal has attacked and injured villagers - ...ren - in half a dozen villages under the Manjhagar...
...betan refugees plan to introduce organic farming i...t organic village will be set up in each of the 12...a," said Ngodup Dorje, head of the agriculture and...f the Tibetan government-in-exile here. The model...
...UN report on drugs has officially declared Britain...aily Mail report, over 900,000 Britons buy cocaine...he biggest user in the continent. In addition, Bri...users are the largest number in any country in Eur...
Other Medicine News:
Catheters are available in two tip styles- the smooth, atraumatic DeLee tip with staggered eyes, and the angled Whistle tip. Two types of catheter valve options, SAFE-T-VAC and TOUCH-TROL, deliver ea
Sterile Straight Packed TOUCH-TROL Suction Catheters
Tracheal Suction Latex Rubber Catheters - Funnel End
Quantel Medical introduces the new Aviso A/B, a new generation high definition ultrasound system in a unique laptop or desktop PC workstation.
Medicine Products: